瑞财经 严明会6月30日，深圳市维琪科技股份有限公司（以下简称：维琪科技）北交所IPO获受理，保 荐机构国信证券，保荐代表人楼瑜、郑桂斌，会计师事务所为致同会计师事务所。 截至招股说明书签署日，公司拥有16个经国家药监局批准备案的化妆品新原料， 其中包括7个创新新原 料，公司新原料备案获批数量位居第一，创新新原料备案获批数量位居第一。维琪科技已进入丸美、宝 洁等国内外知名品牌供应链体系。 丁文锋、赖燕敏夫妻为维琪科技共同实际控制人，二人合计控制公司 62.1%的股权。 董事长兼总经理丁文锋直接持有57.28%的股份，并担任公司员工持股平台维聚康的执行事务合伙人， 通过维聚康间接控制公司1.27%的股份，丁文锋直接和间接合计控制公司 58.55%的股份，为公司控股股 东。 丁文锋，48岁，博士研究生学历，2000年9月至2001年1月就职于深圳市万乐药业有限公司，担任研发人 员；2001年2月至2014年3月就职于康哲医药研究(深圳)有限公司，从事新药研发；2014 年至今就职于维 琪科技，现任公司董事长兼总经理。 | 品牌商 | 产品 | 使用公司新原料 | | --- | --- | --- | | 丸美 ...

Core Viewpoint - The whitening ingredient tranexamic acid is experiencing a resurgence in the skincare market, moving from a previously overlooked status to becoming a popular choice among brands and consumers [1][5][20]. Ingredient Trends - Traditional whitening ingredients like niacinamide, arbutin, and alpha hydroxy acids dominate the market, while tranexamic acid, once popularized by Shiseido, has seen a revival due to new research validating its efficacy [1][5]. - In Q1 2024, tranexamic acid entered the top 10 list of popular cosmetic ingredients, marking a significant increase from its previous ranking of 15 in the same period last year [5][6]. Market Growth - The number of registered products containing tranexamic acid has surged, with 918 new registrations in 2024 and a compound annual growth rate exceeding 80% over the past three years [6][8]. - By May 2025, over 3,000 products featuring tranexamic acid were registered, reflecting a year-on-year growth of over 100% [6][8]. Brand Strategies - Major brands are increasingly incorporating tranexamic acid into their product lines, with companies like OLAY and domestic brands like Proya launching new products featuring this ingredient [14][15]. - The competitive landscape in the whitening market is intensifying, with brands seeking innovative narratives to differentiate their offerings amid a saturated market [13][20]. Research and Development - Procter & Gamble's recent research highlights the mechanism by which tranexamic acid inhibits melanin production, providing a scientific basis for its use in whitening products [10][12]. - The study indicates that tranexamic acid can stabilize melanocytes, preventing excessive melanin transfer to skin cells, thus enhancing its whitening effects [12][13]. Consumer Engagement - The rise of "ingredient-focused" consumers has led to increased discussions about tranexamic acid on social media platforms, indicating growing consumer interest and awareness [17][18]. - However, the lack of a standout product in the market is seen as a barrier to tranexamic acid's widespread adoption, with brands needing to innovate to capture consumer attention [18][19]. Future Outlook - The potential for tranexamic acid to become a leading whitening ingredient hinges on overcoming challenges related to its skin absorption and stability [18][19]. - Innovations such as microneedling combined with tranexamic acid are being explored to enhance its efficacy and safety in topical applications [18][19]. - The cost of tranexamic acid remains a factor, with current prices significantly higher than those of established ingredients like niacinamide, which may limit its market penetration [19][20].

NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year Ended March 31st, 2025 Total revenue in the first quarter was $1 million compared to $0.5 million revenues for the same period in 2024. Research and development expenses were $8.8 million compared to $5.3 million in the same period in 2024. The increase o ...

今天分享的是：小红书运营：「产品玩法速递」美妆个护2025Q1商业产品玩法精选 报告共计：12页 《美妆个护2025Q1商业产品玩法精选》聚焦小红书美妆个护领域商业产品玩法，展示了多个品牌的成功营销案例，为相关从业者提供经验借鉴。在开屏与 H5新样式组合方面，理肤泉和OLAY借助该模式，通过开屏曝光联动明星或展示产品亮点，引导用户跳转H5页面并二跳电商平台，在大促时实现种草和产 品销售转化，OLAY上线一周品牌人群资产增长64%。明星共创笔记成为热门玩法，海蓝之谜借助品牌代言人账号分享生活方式；巴黎欧莱雅进行多明星笔 记共创；薇诺娜携手首席推荐官，都实现了粉丝与品牌人群的联动，引发热度。搜索种草新能力"搜索人群优投"上线，雅诗兰黛通过细分人群、优化精词与 拓展泛词，提升了跑量和点击率，拓展词贡献42%的跑量 ；兰蔻则针对红海品类，拓展低竞争需求词，渗透老钱人群，使老钱人群搜索渗透率环比提升20% 。在计划推广方面，雪玲妃巧用"计划一键起量"测笔记，降低赛马时间成本，起量期间为计划贡献86%的跑量且ROI持平；ELL乘风托管功能结合人群高级 定向，帮助品牌突破闭环笔记放量瓶颈，在信息流场域拿量占比提升40%，广 ...

近日，美国消费品巨头宝洁（P&G）发布2025财年三季报，因美国关税的不确定性，宝洁将2025财年 有机销售额增长预期从3%-5%下调至2%。 宝洁有五大业务，其中第一大营收板块为织物和家庭护理板块（Fabric&Home Care），该板块有汰渍、 碧浪等品牌，报告期内，该板块净销售额同比下滑3%至69.48亿美元，净利润同比下滑1%至12.85亿美 元； 报告期内产品价格涨幅1% 销量下滑1% 前三大营收业务的净销售额及利润均下滑 其次为拥有护舒宝、帮宝适等品牌的婴儿、女性和家庭护理板块（Baby、Feminine& FamilyCare），净 销售额同比下滑4%至47.55亿美元，净利润同比下滑12%至8.80亿美元； 拥有舒肤佳、Olay、SK-II等品牌的美容板块（Beauty）为企业第三大营收板块，其净销售额同比下滑 2%至34.90亿美元，净利润同比下滑8%至5.39亿美元； 拥有佳洁士等品牌的医疗保健板块（Health Care）净销售额与上年持平，为28.80亿美元，净利润同比 增长8%至5.69亿美元； 拥有吉列剃须刀等品牌的理容板块（Grooming）净销售额同比下滑2%至15.05亿美 ...

Core Insights - The article compares Procter & Gamble (PG) and Colgate-Palmolive (CL), highlighting their market positions, financial performance, and strategic priorities within the consumer-packaged goods (CPG) industry [1][2]. Procter & Gamble (PG) - PG operates in over 180 countries with a market capitalization close to $400 billion, offering a diverse product lineup including Tide, Pampers, Gillette, and Olay, which provides a competitive advantage [3]. - In Q3 fiscal 2025, PG reported earnings per share (EPS) of $1.54, meeting analyst expectations, while maintaining or growing market share in seven of its ten core categories [4]. - The company focuses on premiumization and innovation, launching high-performance products and investing in advertising rather than discount promotions, which supports long-term brand strength [5]. - PG anticipates approximately $200 million in after-tax headwinds from commodity costs and foreign exchange in fiscal 2025, alongside projected tariff-related costs of $1-$1.5 billion annually [6]. - The company plans to return $16-17 billion to shareholders through dividends and buybacks, demonstrating a commitment to long-term value creation [7]. Colgate-Palmolive (CL) - CL is a leader in oral care with a 41% share of the global toothpaste market and a 32% share in manual toothbrushes, while also expanding into pet nutrition and skincare [9][10]. - In Q1 2025, CL reported sales exceeding $4.91 billion, beating estimates despite a 3% year-over-year decline, with an EPS of 91 cents also surpassing expectations [11]. - The company expects $200 million in incremental tariff impacts in 2025 but is mitigating these through supply-chain flexibility and productivity gains, having invested $2 billion in U.S. supply-chain upgrades over the past five years [12]. - CL maintains a focus on advertising ROI and AI-driven analytics to optimize spending while continuing to innovate and premiumize its offerings [13]. - The company is positioned to deliver sustainable shareholder value through its strong balance sheet and disciplined execution, despite short-term pressures [14][26]. Financial Estimates - For fiscal 2025, PG's sales and EPS are expected to grow by 0.4% and 3%, respectively, with EPS estimates down by 1.2% in the past week [15]. - CL's sales and EPS estimates suggest year-over-year growth of 0.6% and 1.4%, with EPS estimates down by 0.5% recently [18]. - Both companies have experienced downward estimate revisions, but CL's revisions are less severe compared to PG [20]. Price Performance & Valuation - Year-to-date, PG shares have declined by 3.1%, while CL stock has gained 1.4% [21]. - PG is trading at a forward P/E multiple of 23.06X, below its five-year median of 23.65X, indicating a potentially undervalued position [23]. - CL's forward P/E multiple is at 24.47X, above its five-year median of 24.1X, reflecting its solid fundamentals and growth strategy [24]. Conclusion - PG's extensive global presence and diversified brand portfolio provide a foundation for long-term revenue stability, though it faces geopolitical and market-specific challenges [25]. - CL's strong brand equity and adaptability position it as an attractive investment option, particularly with lower tariff risks and solid fundamentals [27].

Core Points - Sol-Gel Technologies Ltd. announced a 10-for-1 reverse share split to increase the per share market price and regain compliance with Nasdaq's minimum bid price requirement [4][5][6] Group 1: Reverse Share Split Details - The reverse share split will consolidate every ten ordinary shares into one ordinary share, effective at 11:59 p.m. Eastern Time on May 2, 2025 [3][5] - The first trading day on Nasdaq under the new share structure is expected to be May 5, 2025, with the symbol "SLGL" remaining unchanged [3][4] - The par value of the ordinary shares will increase from NIS 0.1 to NIS 1.0, and the total share capital will adjust from 50 million to 5 million ordinary shares [6] Group 2: Shareholder Approval and Process - Shareholders approved the reverse split ratio at a special meeting on April 1, 2025, with the board of directors confirming the 10-for-1 ratio on April 9, 2025 [2] - Equiniti Trust Company, LLC will act as the exchange and transfer agent for the reverse split, and shareholders holding shares electronically will not need to take action to receive post-split shares [7] Group 3: Company Overview - Sol-Gel Technologies is focused on developing and commercializing drug products for skin diseases, with FDA-approved products including TWYNEO for acne and EPSOLAY for rosacea [8] - The company's pipeline includes SGT-610, an orphan drug candidate for Gorlin syndrome, and SGT-210, a topical drug candidate for rare skin keratodermas [9]

温和、不及预期……成为宝洁2025财年三季度（2025年1－3月）业绩的标签。2025财年三季度，宝洁实 现净销售额为198亿美元，较上年同期下降2%；净利润约38亿美元，与去年基本持平。从表现来看，宝 洁三季度业绩低于分析师预期的201.1亿美元。根据LSEG数据，市场原本预计销售额仅下滑0.44%。 对于本季度的业绩情况，宝洁CEO乔恩·莫勒对外表示："在充满挑战的消费市场下，本季度我们实现了 温和的有机销售额和每股收益增长。我们正在对近期前景进行适当调整，以反映潜在的市场状况。" 宝洁管理层对外表示，"我们正在对近期前景作出适当调整，以反映潜在的市场状况，同时对我们品牌 和竞争市场的长期增长前景保持信心。我们仍然致力于我们的综合增长战略，即专注于日常用品类别的 产品组合。我们将继续投资于不同价位的卓越创新，以提高消费者价值并推动品类增长"。 在接下来的发展中，宝洁也将提价策略作为提振其业绩的一种重要手段。莫勒在财报电话会议上提 及"公司可能在7月开始的新财年实施提价"。 可现实情况是涨价策略大概率不会一直都是宝洁的万能牌。 根据公开数据，2024财年，宝洁旗下五大部门——美容、男士理容、健康护理、织物和 ...

Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b tri ...